Kailera Therapeutics, Inc.
KLRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002096997
No open-market purchases or sales by Kailera Therapeutics, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $2.57B in total; Soros Fund Management is the only superinvestor holding it.
Superinvestors holding KLRA, Q2 2026
1 superinvestor reports holding Kailera Therapeutics, Inc. on Form 13F, worth $440.6K in total. Weight is Kailera Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Soros Fund ManagementGeorge Soros | <0.1% | 20,000 | $440.6K | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of KLRA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end